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The clinical significance of elevated amylase and/or lipase levels in asymptomatic subjects has not been established yet. However, serum amylase and lipase levels are increasingly being examined as part of a routine check-up or during health examination in the absence of symptoms. When pancreatic enzymes are elevated, presence of pancreatitis is first suspected, but if there is no definite evidence of pancreatitis, other pancreatic and extra-pancreatic diseases are considered to explain the elevation of pancreatic enzymes. Other causes that can lead to this condition run the gamut from drugs, anatomical abnormalities of the pancreas, salivary diseases, gastrointestinal diseases, gynecologic diseases, neoplasms, renal failure, macroamylasemia to chronic non-pathological pancreatic hyperenzymemia (CNPH). Imaging tools that can aid in making the diagnosis include abdominal ultrasonography, computed tomography (CT) scan, magnetic resonance cholangiopancreatography (MRCP), MRCP with secretin stimulation (MRCP-S), and endoscopic ultrasound (EUS). The most frequently used imaging modality for diagnosing pancreatitis is CT scan despite its limitations such as inability to identify subtle morphological changes in the pancreas, radiation exposure, and possible occurrence of contrast induced side effects. Endoscopic retrograde cholangiopancreatography (ERCP) is the standard test for diagnosing chronic pancreatitis, which can best demonstrate changes in the pancreatic duct. However, since complications can occur in up to 3%--7% of patients, ERCP is usually performed for therapeutic purposes rather than simply for making diagnosis. Because of the inherent limitations of the aforementioned studies, attempts have been made to detect all possible abnormalities of the pancreas by using tests such as EUS, MRCP, and MRCP-S. MRCP is a noninvasive test that is useful for diagnosing structural abnormalities of the pancreas, and MRCP-S is particularly useful for diagnosing abnormalities of side branch pancreatic duct and delayed main pancreatic duct emptying \[[@b1-ce-2019-044]-[@b4-ce-2019-044]\]. EUS is considered to be a highly sensitive test for examining various lesions of the pancreatic duct and parenchyma, and is especially useful for diagnosing chronic pancreatitis compared to other imaging modalities \[[@b4-ce-2019-044],[@b5-ce-2019-044]\].

In the current issue of *Clinical Endoscopy*, Sitaraman et al. analyzed the usefulness of EUS in patients with isolated elevation of amylase and/or lipase but without pancreatitis or pancreatobiliary disease on noninvasive imaging modalities, such as abdominal ultrasound, CT scan, and MRCP \[[@b6-ce-2019-044]\]. This baffling situation has previously been pondered upon by many scientists, and in the 1970s, some researchers like Warshaw and Lee pointed out that excessive examinations should be provided only on the assumption that pancreatic hyperenzymemia was pathologic \[[@b7-ce-2019-044]\]. Two decades later in 1996, Gullo reported the result of 18 asymptomatic patients with chronic (\>6 months) pancreatic enzyme elevation who were extensively assessed but no pancreatic pathology was determined, and defined this condition as CNPH \[[@b8-ce-2019-044]\]. The authors were concerned by that fact that although CNPH patients are more likely to have no specific disease, blood tests and various imaging studies were repeatedly performed and patients' economic burden was increased, leading to deterioration of the quality of life \[[@b8-ce-2019-044]\]. Then how should we deal with these patients and what examination should we pursue? Alternatively, it is really necessary even to continue on with additional examination?

There have been multiple studies that looked into the value of MRCP, MRCP-S, and EUS in assessing serum pancreatic enzyme elevation in the absence of definite pancreatic diseases. Studies which assessed the role of MRCP for diagnosing early chronic pancreatitis demonstrated that the sensitivity and specificity were 92% and 75%, respectively \[[@b9-ce-2019-044],[@b10-ce-2019-044]\]. The incidence of pancreatic cystic lesions found on MRCP was reported to range from 2.4% to 19.6%, which was not significantly different from the previously reported autopsy data \[[@b11-ce-2019-044]\]. Some researchers have emphasized the need for employing MRCP-S because MRCP-S can improve the diagnosis rate of early chronic pancreatitis \[[@b12-ce-2019-044],[@b13-ce-2019-044]\]. MRCP-S has been reported to be able to more clearly confirm the dilatation of the pancreatic duct compared to conventional MRCP \[[@b1-ce-2019-044]\]. However, given the fact that additional findings found on MRCP-S are also benign, the clinical significance of MRCP-S is still limited. Other researchers insisted that not only MRCP-S but also EUS should be performed to confirm pancreatic abnormalities \[[@b14-ce-2019-044]\]. However, EUS is an expensive and invasive test that is highly dependent on the proficiency of the examiner. Moreover, there are innate limitations to the accuracy of the Rosemont criteria in diagnosing early chronic pancreatitis \[[@b15-ce-2019-044]\]. Considering these facts, it is difficult to say that combined EUS & MRCP-S examinations have superiority and suitability compared to MRCP alone \[[@b5-ce-2019-044]\].

Then what value would EUS have when used alone to examine patient with pancreatic hyperenzymemia but without pancreatobiliary diseases on previous imaging studies? In the current study by Sitaraman et al., the authors suggest that EUS is helpful in this subset of patients since it provides a probable diagnosis in 53% of those with previously normal imaging and contributes to arrive at a diagnosis in 42.8% even when asymptomatic \[[@b6-ce-2019-044]\]. These results are somewhat consistent with those of previous papers \[[@b1-ce-2019-044],[@b14-ce-2019-044]\]. Testoni et al. showed that the percentage of abnormalities found in CNPH patients and controls using MRCP-S were 52% and 7.1%, respectively \[[@b1-ce-2019-044]\]. Di Leo et al. found that the percentage of normal EUS findings in CNPH group and control group were observed in 39.7% and 86.8%, respectively \[[@b14-ce-2019-044]\]. CNPH is a diagnosis of exclusion and all pancreas-related diseases must be ruled out before ascertaining that it is truly a benign condition. In this regards, it seems reasonable to conduct additional and aggressive tests to detect pancreatobiliary pathology in those with CNPH since clinically significant positive findings that can explain elevation of amylase and/or lipase are not infrequently found on MRCP-S and/or EUS.

The study by Sitaraman et al. is a retrospective study with some limitations such as lack of data on alcohol abuse and medication history, and selection bias incurred by selecting only those who underwent EUS examination \[[@b6-ce-2019-044]\]. In addition, the study population does not seem to have undergone blood test such as iso-amylase, which could be quite useful in differentiating and ruling out hyperamylasemia of salivary or other origins. Nevertheless, this study can be said to be meaningful in that it refocused the usefulness of EUS in evaluating patients with isolated serum amylase and/or lipase elevations. It remains to be proven which of the two, MRCP-S or EUS, is better in evaluating this condition. EUS might be a good next evaluation step, especially if secretin is not available to carry out MRCP-S as is the situation in Korea. Whichever method is employed, it could particularly be helpful for evaluating those presumed to have CNPH.
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